EMEA-001943-PIP02-20
Key facts
| Invented name |
Ultomiris
|
| Active substance |
ravulizumab
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0399/2021
|
| PIP number |
EMEA-001943-PIP02-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment in haematopoietic stem cell transplantation
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|